the potential of bispecific antibody-containing combinations in patients with b-cell lymphomas
Published 3 months ago • 125 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
2:39
the role of bispecific antibodies in the treatment landscape for r/r dlbcl
-
1:45
the role of non-covalent btkis in the era of covalent btkis for b-cell malignancies
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
2:39
advancements in bispecific and trispecific antibodies for the treatment of lymphoma
-
1:03
using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in b-all
-
2:56
the exciting future of bispecific antibodies
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
1:00:47
aureka's high throughput bispecific antibody discovery pipeline - lock and key webinar
-
6:29
how are nk cells being used in anti-myeloma therapy?
-
1:01:08
comparing bispecific antibody format feasibility
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
1:09
outpatient dosing of bispecific antibodies: what do clinicians need to consider?
-
0:58
first-in-human trial of cln-978, a novel cd19 bispecific antibody, for the treatment of r/r b-nhl
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
3:10
understanding resistance mutations with covalent and non-covalent btkis
-
6:15
how to manage and report aes associated with bispecific antibody treatment in myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
4:12
bispecific antibodies in italy: current status and future outlooks
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
2:33
the effect of lymphodepleting agents on rate and severity of toxicities following car-t infusion